Article Text

Download PDFPDF
General and Risk Management, Patient Safety (including: medication errors, quality control)
Monitoring of Pharmaceutical Care Hepatitis C program (2007-2011)
  1. J.M. Rodríguez Camacho,
  2. V. Vázquez Vela,
  3. M.J. Huertas Fernández,
  4. M.V. Manzano Martín,
  5. M.J. Martínez Bautista,
  6. L. Obel Gil
  1. 1H.U. Puerta del Mar, Farmacia, Cádiz, Spain


Background Pharmaceutical care(PC) is the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient's quality of life.

Purpose To analyse the results of a PC program in patients who are infected with the virus of hepatitis C(HCV).

Materials and Methods Period of study: April 2007-October 2011. It was aimed to prevent, detect and resolve medication-related problems (MRPs) in HCV patients. Phases: First visit: Prescription validation, medical history revision and elaboration of patient medical record. The authors inform patients about adverse reactions, interactions and healthy lifestyle habits. The authors stress the importance of treatment compliance in order to obtain a sustained viral response and how to minimise the side effects. Subsequent visits: Personalised monitoring, detection of MRPs and Pharmaceutical Intervention (PI). The authors establish visiting hours and evaluate the adherence to the pharmacotheraphy. The adherence calculation is done through dispensing registers. The adherent patient endorses the rule 80/80/80:80% of interferon (IFN), ribavirin (RBV) doses and 80% of the treatment time in relation to the genotype.

Results 542 interviews were done in 365 patients under IFN and RBV treatment: oral information 67.16% and both oral and written 32.84%. Face to face interviews 90.22% and telephone ones 9.41%. 27.86% to start the treatment, 69.74% during the treatment, 0.55% by treatment change, 1.66% possible interaction and others 0.18%. Counselling reasons (227), the most frequent were: tiredness 15.86%, mental disorders 11,89%, reaction at the injection site 8.81%, gastrointestinal discomfort 8.81%, pseudo-flu syndrome 8.37%, insomnia 6.61% and pruritus 6.61%. 536 PI were accepted, with recommendations about healthy lifestyle habits and some pieces of advice on medication administration and handling side effects. In 45 times, patients were referred to the specialist doctor.

Conclusions The majority of the patients applied for PC during the pharmacotheraphy follow-up, above all, by side effects related to medication. The interviews with the patients reinforce the information on their pharmacotheraphy in order to minimise side effects and resolve MRPs. The PC program in HCV patients helps to improve the safe use of medications and avoids unnecessary visits to the specialist doctor.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.